Immunotherapy advances in uro-genital malignancies. Review uri icon



  • Immunotherapy for the treatment of cancer has made significant progresses over the last 20 years. Multiple efforts have been attempted to restore immune-mediated tumor elimination, leading to the development of several targeted immunotherapies. Data from recent clinical trials suggest that these agents might improve the prognosis of patients with advanced genito-urinary (GU) malignancies. Nivolumab has been the first immune checkpoint-inhibitor approved for pre-treated patients with metastatic renal cell carcinoma. Pembrolizumab and atezolizumab have shown promising results in both phase I and II trials in urothelial carcinoma. Brentuximab vedotin has demonstrated early signals of clinical activity and immunomodulatory effects in highly pre-treated patients with testicular germ cell tumors. In this review, we have summarized the major clinical achievements of immunotherapy in GU cancers, focusing on immune checkpoint blockade as well as the new immunomodulatory monoclonal antibodies (mAbs) under clinical evaluation for these malignancies.

publication date

  • June 17, 2016



  • Cancer Vaccines
  • Immunotherapy
  • Urogenital Neoplasms


Scopus Document Identifier

  • 84977602356

Digital Object Identifier (DOI)

  • 10.1016/j.critrevonc.2016.06.012

PubMed ID

  • 27372200

Additional Document Info


  • 105